HIV protease: Enzyme function and drug resistance

Ala, 1997, Molecular basis of HIV-1 protease drug resistance: Structural analysis of mutant proteases complexed with cyclic urea inhibitors, Biochemistry, 36, 1573, 10.1021/bi962234u Ala, 1998, Molecular recognition of cyclic urea HIV-1 protease inhibitors, J. Biol. Chem., 273, 12325, 10.1074/jbc.273.20.12325 Baldwin, 1995, Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine, Structure, 3, 581, 10.1016/S0969-2126(01)00192-7 Baldwin, 1995, Structural basis of drug resistance for the V82A mutant of HIV-1 proteinase, Nat. Struct. Biol., 2, 244, 10.1038/nsb0395-244 Barrie, 1996, Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/polpolyproteins: Amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1, Virology, 219, 407, 10.1006/viro.1996.0266 Barry, 1997, Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations, Clin. Pharmacokinet., 32, 194, 10.2165/00003088-199732030-00003 Billich, 1990, Purification, assay and kinetic features of HIV-1 proteinase, Biol. Chem. Hoppe-Seyler, 371, 265, 10.1515/bchm3.1990.371.1.265 Boden, 1998, Resistance to human immunodeficiency virus type 1 protease inhibitors, Antimicrob. Agents Chemother., 42, 2775, 10.1128/AAC.42.11.2775 Carrillo, 1998, In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor, J. Virol., 72, 7532, 10.1128/JVI.72.9.7532-7541.1998 Chen, 1995, Three-dimensional structure of a mutant HIV-1 protease displaying cross-resistance to all protease inhibitors in clinical trials, J. Biol. Chem., 270, 21433, 10.1074/jbc.270.37.21433 Cheng, 1990, Stability and activity of human immunodeficiency virus protease: Comparison of the natural dimer with a homologous, single-chain tethered dimer, 87, 9660 Coffin, 1995, HIV population dynamics in vivo: Implications for genetic variation, pathogenesis and therapy, Science, 267, 483, 10.1126/science.7824947 1997 Collins, 1995, Flap opening in HIV-1 protease simulated by ‘activated’ molecular dynamics, Nat. Struct. Biol., 2, 334, 10.1038/nsb0495-334 Condra, 1995, In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors, Nature (London), 374, 569, 10.1038/374569a0 Condra, 1996, Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor, J. Virol., 70, 8270, 10.1128/JVI.70.12.8270-8276.1996 Cornelissen, 1997, pol gene diversity of five human immunodeficiency virus type 1 subtypes: Evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D, J. Virol., 71, 6348, 10.1128/JVI.71.9.6348-6358.1997 Croteau, 1997, Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors, J. Virol., 71, 1089, 10.1128/JVI.71.2.1089-1096.1997 Darke, 1994, Stability of dimeric retroviral proteases, Vol. 241, 104 Darke, 1994, Dissociation and association of the HIV-1 protease dimer subunits: Equilibria and rates, Biochemistry, 33, 98, 10.1021/bi00167a013 Davies, 1990, The structure and function of the aspartic proteinases, Annu. Rev. Biophys. Biomol. Struct., 19, 189, 10.1146/annurev.biophys.19.1.189 Debouck, 1992, The HIV-1 protease as a therapeutic target for AIDS, AIDS Res. Hum. Retroviruses, 8, 153, 10.1089/aid.1992.8.153 Debouck, 1987, Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor, 84, 8903 Deeks, 1997, HIV-1 protease inhibitors. A review for clinicians, JAMA, J. Am. Med. Assoc., 277, 145, 10.1001/jama.1997.03540260059037 Dorsey, 1994, L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor, J. Med. Chem., 37, 3443, 10.1021/jm00047a001 Doyon, 1996, Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors, J. Virol., 70, 3763, 10.1128/JVI.70.6.3763-3769.1996 Dunn, 1994, Subsite preferences of retroviral proteinases, Vol. 241, 254 Eastman, 1998, Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (norvir) monotherapy, J. Virol., 72, 5154, 10.1128/JVI.72.6.5154-5164.1998 Erickson, 1990, Design, activity, and 2.8 Å crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease, Science, 249, 527, 10.1126/science.2200122 Erickson, 1995, The not-so-great escape, Nat. Struct. Biol., 2, 523, 10.1038/nsb0795-523 Erickson, 1996, Structural mechanisms of HIV drug resistance, Annu. Rev. Pharmacol. Toxicol., 36, 545, 10.1146/annurev.pa.36.040196.002553 Erickson, 1999, HIV protease as a target for the design of antiviral agents for AIDS, 1 Erickson, 1999, Protease inhibitors: Resistance, cross-resistance, fitness and the choice of initial and salvage therapies, AIDS, 13, S189 Ermolieff, 1997, Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance in vivo, Biochemistry, 36, 12364, 10.1021/bi971072e Ferguson, 1991, Determination of the relative binding free energies of peptide inhibitors to the HIV-1 protease, J. Med. Chem., 34, 2654, 10.1021/jm00112a048 Flexner, 1998, HIV-protease inhibitors, N. Engl. J. Med., 338, 1281, 10.1056/NEJM199804303381808 Freire, 1990, Isothermal titration calorimetry. Direct thermodynamic characterization of biological molecular interactions, Anal. Chem., 62, 950A, 10.1021/ac00217a002 Furfine, 1992, Two-step binding mechanism for HIV protease inhibitors, Biochemistry, 31, 7886, 10.1021/bi00149a020 Grant, 1992, Use of protein unfolding studies to determine the conformational and dimeric stabilities of HIV-1 and SIV protease, Biochemistry, 31, 9491, 10.1021/bi00154a023 Griffiths, 1992, Different requirements for productive interaction between the active site of HIV-1 proteinase and substrates containing -hydrophobic∗ hydrophobic- or -aromatic∗pro- cleavage sites, Biochemistry, 31, 5193, 10.1021/bi00137a015 Gulnik, 1995, Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure, Biochemistry, 34, 9282, 10.1021/bi00029a002 Hammond, 1997, Mutation in retroviral genes associated with drug resistance, III Harte, 1993, Prediction of the protonation state of the active site aspartyl residues in HIV-1 protease-inhibitor complexes via molecular dynamics simulation, J. Am. Chem. Soc., 115, 3883, 10.1021/ja00063a005 Hellen, 1994, Assay methods for retroviral proteases, Vol. 241, 46 Henderson, 1988, Molecular characterization of gag proteins from simian immunodeficiency virus (SIVMne), J. Virol., 62, 2587, 10.1128/JVI.62.8.2587-2595.1988 Hertogs, 1998, Patterns of cross-resistance among protease inhibitors in over 1500 clinical HIV-1 isolates. Comparison of genotypic and phenotypic resistance profiles, 49 Ho, 1994, Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor, J. Virol., 68, 2016, 10.1128/JVI.68.3.2016-2020.1994 Hodge, 1996, Improved cyclic urea inhibitors of the HIV-1 protease: Synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450, Chem. Biol., 3, 301, 10.1016/S1074-5521(96)90110-6 Hoog, 1996, Human immunodeficiency virus protease ligand specificity conferred by residues outside of the active site cavity, Biochemistry, 35, 10279, 10.1021/bi960179j Hui, 1993, Large scale purification and refolding of HIV-1 protease from Escherichia coli inclusion bodies, J. Protein Chem., 12, 323, 10.1007/BF01028194 Hyland, 1991, Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism, Biochemistry, 30, 8454, 10.1021/bi00098a024 Ido, 1991, Kinetic studies of human immunodeficiency virus type 1 protease and its active-site hydrogen vond mutant A28S, J. Biol. Chem., 266, 24359, 10.1016/S0021-9258(18)54237-X Jacobsen, 1996, In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: Mutations, kinetics, and frequencies, J. Infect. Dis., 173, 1379, 10.1093/infdis/173.6.1379 Jadhav, 1997, Cyclic urea amides: HIV-1 protease inhibitors with low nanomolar potency against both wild type and protease inhibitor resistant mutants of HIV, J. Med. Chem., 40, 181, 10.1021/jm960586t Jordan, 1992, Activity and dimerization of human immunodeficiency virus protease as a function of solvent composition and enzyme concentration, J. Biol. Chem., 267, 20028, 10.1016/S0021-9258(19)88660-X Kaldor, 1997, Viracept (nelfinavir mesylate, AG1343): A potent, orally bioavailable inhibitor of HIV-1 protease, J. Med. Chem., 40, 3979, 10.1021/jm9704098 Kaplan, 1991, Human immunodeficiency virus type 1 Gag proteins are processed in two cellular compartments, 88, 4528 Kaplan, 1993, Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles, J. Virol., 67, 4050, 10.1128/JVI.67.7.4050-4055.1993 Kaplan, 1994, The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency, J. Virol., 68, 6782, 10.1128/JVI.68.10.6782-6786.1994 Kaplan, 1994, Selection of multiple human immunodeficiency virus type 1 variants that encode viral proteases with decreased sensitivity to an inhibitor of the viral protease, 91, 5597 Katoh, 1987, Inhibition of retroviral protease activity by an aspartyl proteinase inhibitor, Nature (London), 329, 654, 10.1038/329654a0 Kempf, 1995, ABT-538 is a potent inhibitor of human immunodeficiency virus protease and as high oral bioavailability in humans, 92, 2484 Kempf, 1998, The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir, AIDS, 12, F9, 10.1097/00002030-199805000-00001 Kim, 1996, New series of potent, orally bioavailable, non-peptidic cyclic sulfones as HIV-1 protease inhibitors, J. Med. Chem., 39, 3431, 10.1021/jm960340o Kisselev, 1997, Cleavage of the complement system C3 component by HIV-1 proteinase, Biol. Chem. Hoppe-Seyler, 378, 439 Klabe, 1998, Resistance to HIV protease inhibitors: A comparison of enzyme inhibition and antiviral potency, Biochemistry, 37, 8735, 10.1021/bi972555l Kohl, 1988, Active human immunodeficiency virus protease is required for viral infectivity, 85, 4686 Konvalinnka, 1990, Sub-site preferences of the aspartic proteinase from the human immunodeficiency virus, HIV-1, FEBS Lett., 268, 35, 10.1016/0014-5793(90)80966-M Konvalinka, 1992, An engineered retroviral proteinase from myeloblastosis associated virus acquires pH dependence and substrate specificity of the HIV-1 proteinase, EMBO J., 11, 1141, 10.1002/j.1460-2075.1992.tb05154.x Korant, 1997, The HIV protease and therapies for AIDS, Adv. Exp. Med. Biol., 421, 279, 10.1007/978-1-4757-9613-1_37 Korant, 1998, A cellular anti-apoptosis protein is cleaved by the HIV-1 protease, Adv. Exp. Med. Biol., 436, 27, 10.1007/978-1-4615-5373-1_3 Kotler, 1992, Human immunodeficiency virus type 1 Gag-protease fusion proteins are enzymatically active, J. Virol., 66, 6781, 10.1128/JVI.66.11.6781-6783.1992 Kotler, 1997, Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro, J. Virol., 71, 5774, 10.1128/JVI.71.8.5774-5781.1997 Kozal, 1996, Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays, Nat. Med., 2, 753, 10.1038/nm0796-753 Krafft, 1994, Synthetic approaches to continuous assays of retro-viral proteases, Vol. 241, 70 Kramer, 1986, HTLV-III gag protein is processed in yeast cells by the virus pol-protease, Science, 231, 1580, 10.1126/science.2420008 Kräusslich, 1995, The spacer peptide between human immonodeficiency virus capsid and nucleocapsid proteins is essential for ordered assembly and viral infectivity, J. Virol., 69, 3407, 10.1128/JVI.69.6.3407-3419.1995 Kuzmic, 1993, Stabilization of HIV proteinase dimer by bound substrate, Biochem. Biophys. Res. Commun., 194, 301, 10.1006/bbrc.1993.1819 Ladbury, 1996, Sensing the heat: The application of isothermal titration calorimetry to the thermodynamic studies of biomolecular interactions, Chem. Biol., 3, 791, 10.1016/S1074-5521(96)90063-0 Lam, 1994, Rational design of potent, bioavailable, nonpeptide cyclic ureas as HIV protease inhibitors, Science, 263, 380, 10.1126/science.8278812 Lapatto, 1989, X-ray analysis of HIV-1 proteinase at 2.7Å resolution confirms structural homology among retroviral enzymes, Nature (London), 342, 299, 10.1038/342299a0 Lech, 1996, In vivo sequence diversity of the protease of human immunodeficiency virus type 1: Presence of protease inhibitor-resistant variants in untreated subjects, J. Virol., 70, 2038, 10.1128/JVI.70.3.2038-2043.1996 Lee, 1996, Design, synthesis, and characterization of dipeptide isostere containing cis-epoxide for the irreversible inactivation of HIV protease, Bioorg. Med. Chem. Lett., 6, 589, 10.1016/0960-894X(96)00087-X Luque, 1998, Molecular basis of resistance to HIV-1 protease inhibition: A plausible hypothesis, Biochemistry, 37, 5791, 10.1021/bi9802521 Mammano, 1998, Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients, J. Virol., 72, 7632, 10.1128/JVI.72.9.7632-7637.1998 Markowitz, 1995, Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor, J. Virol., 69, 701, 10.1128/JVI.69.2.701-706.1995 Martinez-Picado, 1999, Replicative fitness of protease inhibitor resistant mutants of human immunodeficiency virus type 1, J. Virol., 73, 3744, 10.1128/JVI.73.5.3744-3752.1999 Maschera, 1996, Human immunodeficiency virus. Mutations in the viral protease that confer resistance to saquinavir increase the dissociation rate constant of the protease-saquinavir complex, J. Biol. Chem., 271, 33231, 10.1074/jbc.271.52.33231 McQuade, 1990, A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation, Science, 247, 454, 10.1126/science.2405486 Meek, 1989, Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease, 86, 1841 Meek, 1994, Use of steady state kinetic methods to elucidate the kinetic and chemical mechanisms of retroviral proteases, Vol. 241, 127 Mildner, 1994, The HIV-1 protease as enzyme and substrate: Mutagenesis of autolysis sites and generation of a stable mutant with retained kinetic properties, Biochemistry, 33, 9405, 10.1021/bi00198a005 Molla, 1996, Ordered accumulation of mutations in HIV protease confers resistance to ritonavir, Nat Med., 2, 760, 10.1038/nm0796-760 Molla, 1998, Recent developments in HIV protease inhibitor therapy, Antiviral Res., 39, 1, 10.1016/S0166-3542(98)00011-4 Moyle, 1996, Current knowledge and future prospects for the use of HIV protease inhibitors, Drugs, 51, 701, 10.2165/00003495-199651050-00001 Murphy, 1992, Thermodynamics of structural stability and cooperative folding behavior in proteins, Adv. Protein Chem., 43, 313, 10.1016/S0065-3233(08)60556-2 Navia, 1989, Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1, Nature (London), 337, 615, 10.1038/337615a0 Nijhuis, 1999 Nillroth, 1997, Human immunodeficiency virus type 1 proteinase resistance of symmetric cyclic urea inhibitor analogs, Antimicrob. Agents Chemother., 41, 2383, 10.1128/AAC.41.11.2383 Noble, 1996, Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection, Drugs, 52, 93, 10.2165/00003495-199652010-00007 Pargellis, 1994, Determination of kinetic rate constants for the binding of inhibitors to HIV-1 protease and for the association and dissociation of active homodimer, Biochemistry, 33, 12527, 10.1021/bi00207a021 Park, 1995, Rational design of irreversible, pseudo-C2-symmetric HIV-1 protease inhibitors, Bioorg. Med. Chem. Lett., 5, 1843, 10.1016/0960-894X(95)00306-E Partaledis, 1995, In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease, J. Virol., 69, 5228, 10.1128/JVI.69.9.5228-5235.1995 Patick, 1995, Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor, J. Virol., 69, 2148, 10.1128/JVI.69.4.2148-2152.1995 Patick, 1996, Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease, Antimicrob. Agents Chemother., 40, 292, 10.1128/AAC.40.2.292 Pazhanisamy, 1996, Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants, J. Biol. Chem., 271, 17979, 10.1074/jbc.271.30.17979 Pearl, 1987, A structural model for the retroviral proteases, Nature (London), 329, 351, 10.1038/329351a0 Pettit, 1994, The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectio virions, J. Virol., 68, 8017, 10.1128/JVI.68.12.8017-8027.1994 Phylip, 1990, Hydrolysis of synthetic chromogenic substrates by HIV-1 and HIV-2 proteinases, Biochem. Biophys. Res. Commun., 171, 439, 10.1016/0006-291X(90)91412-L Polgár, 1994, Substrate-dependent mechanisms in the catalysis of human immunodeficiency virus protease, Biochemistry, 33, 9351, 10.1021/bi00197a040 Poorman, 1991, A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base, J. Biol. Chem., 266, 14554, 10.1016/S0021-9258(18)98722-3 Prasad, 1995, HIV protease inhibitors possessing a novel, high affinity and achiral P1/P2 ligand with unique pattern of in vitro resistance. Importance of conformationally-restricted template in the design of enzyme inhibitors, J. Am. Chem. Soc., 117, 11070, 10.1021/ja00150a005 Prasad, 1996, Nonpeptidic potent HIV-1 protease inhibitors, Drug Des. Discovery, 13, 15 Quere, 1996, Triterpenes as potential dimerization inhibitors of HIV-1 protease, Biochem. Biophys. Res. Commun., 227, 484, 10.1006/bbrc.1996.1533 Richards, 1990, Sensitive, soluble chromogenic substrates for HIV-1 proteinase, J. Biol. Chem., 265, 7733, 10.1016/S0021-9258(19)38989-6 Ridky, 1995, Development of drug resistance to HIV-1 protease inhibitors, J. Biol. Chem., 270, 29621, 10.1074/jbc.270.50.29621 Ridky, 1998, Drug-resistant HIV-1 proteases identify enzyme residues important for substrate selection and catalytic rate, Biochemistry, 37, 13835, 10.1021/bi980612k Riviere, 1991, Processing of the precursor of NF-kappa B by the HIV-1 protease during acute infection, Nature (London), 350, 625, 10.1038/350625a0 Roberts, 1998, Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: Theory and practice, AIDS, 12, 453, 10.1097/00002030-199805000-00005 Roberts, 1990, Rational design of peptide-based HIV proteinase inhibitors, Science, 248, 358, 10.1126/science.2183354 Rose, 1993, Regulation of autoproteolysis of the HIV-1 and HIV-2 proteases with engineered amino acid substitutions, J. Biol. Chem., 268, 11939, 10.1016/S0021-9258(19)50290-3 Rose, 1994, Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity, J. Virol., 69, 2751, 10.1128/JVI.69.5.2751-2758.1995 Rose, 1998, Domain flexibility in retroviral proteases: Structural implications for drug resistant mutations, Biochemistry, 37, 2606, 10.1021/bi9716074 Rose, 1996, Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors, 93, 1648 Schechter, 1967, On the size of the active site in proteases. I. Papain, Biochem. Biophys. Res. Commun., 27, 157, 10.1016/S0006-291X(67)80055-X Schock, 1996, Mutational anatomy of an HIV-1 protease variant conferring cross-resistance to protease inhibitors in clinical trials. Compensatory modulations of binding and activity, J. Biol. Chem., 271, 31957, 10.1074/jbc.271.50.31957 Schramm, 1996, The inhibition of human immunodeficiency virus proteases by ‘interface peptides’, Antiviral Res., 30, 155, 10.1016/0166-3542(96)00940-0 Seelmeier, 1988, Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A, 85, 6612 Shafer, 1998, Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients, Ann. Intern. Med., 128, 906, 10.7326/0003-4819-128-11-199806010-00008 Shoeman, 1993, Cleavage of human and mouse cytoskeletal and sarcomeric proteins by human immunodeficiency virus type 1 protease: Actin, desmin, myosin, and tropomyosin, Am. J. Pathol., 142, 221 Silva, 1996, Inhibition and catalytic mechanism of HIV-1 aspartic protease, J. Mol. Biol., 255, 321, 10.1006/jmbi.1996.0026 Smidt, 1997, A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A, Antimicrob. Agents Chemother., 31, 515, 10.1128/AAC.41.3.515 Smith, 1996, Ionization states of the catalytic residues in HIV-1 protease, Nat. Struct. Biol., 3, 946, 10.1038/nsb1196-946 Snasel, 1996, The cleavage of host cell proteins by HIV-1 protease, Folia Biol., 42, 227 Stebbins, 1994, Expression systems for retroviral proteases, Vol. 241, 3 Strickler, 1989, Characterization and autoprocessing of precursor and mature forms of human immunodefiency virus type 1 (HIV 1) protease purified from Escherichia coli, Proteins, 6, 139, 10.1002/prot.340060205 Szeltner, 1996, Rate-determining steps in HIV-1 protease catalysis. The hydrolysis of the most specific substrate, J. Biol. Chem., 271, 32180, 10.1074/jbc.271.50.32180 Tang, 1995, A kinetic model for comparing proteolytic processing activity and inhibitor resistance potential of mutant HIV-1 proteases, FEBS Lett., 367, 112, 10.1016/0014-5793(95)00547-M Tang, 1978, Structural evidence for gene duplication in the evolution of the acid proteases, Nature (London), 271, 618, 10.1038/271618a0 Tawa, 1998, Calculation of relative binding free energies of peptidic inhibitors to HIV-1 protease and its I84V mutant, J. Am. Chem. Soc., 120, 8856, 10.1021/ja9733090 Thaisrivongs, 1996, Structure-based design of HIV protease inhibitors: Sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors, J. Med. Chem., 39, 4349, 10.1021/jm960541s Todd, 1998, The structural stability of the HIV-1 protease, J. Mol. Biol., 283, 475, 10.1006/jmbi.1998.2090 Toh, 1985, Retroviral protease-like sequence in the yeast transposon Ty1, Nature (London), 315, 691, 10.1038/315691a0 Tomasselli, 1994, Specificity of retroviral proteases: An analysis of viral and nonviral protein substrates, Vol. 241, 279 Tomasselli, 1991, Calcium-free calmodulin is a substrate of proteases from human immunodeficiency viruses 1 and 2, Proteins, 10, 1, 10.1002/prot.340100102 Tomasselli, 1991, Actin, troponin C, Alzheimer amyloid precursor protein and pro-interleukin 1β as substrates of the protease from human immunodeficiency virus, J. Biol. Chem., 266, 14548, 10.1016/S0021-9258(18)98721-1 Tozser, 1992, Kinetic and modeling studies of S3-S3′ subsites of HIV proteinases, Biochemistry, 31, 4793, 10.1021/bi00135a008 Vacca, 1994, Design of tight-binding human immunodeficiency virus type 1 protease inhibitors, Vol. 241, 311 Vacca, 1997, Clinically effective HIV-1 protease inhibitors, Drug Des. Discovery, 2, 261, 10.1016/S1359-6446(97)01053-2 Vacca, 1994, L-735, 524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor, 91, 4096 Vogt, 1996, Proteolytic processing and particle maturation, Curr. Top. Microbiol. Immunol., 214, 95, 10.1007/978-3-642-80145-7_4 Wang, 1996, Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272, Biochemistry, 35, 9945, 10.1021/bi961268z West, 1995, Targeting HIV-1 protease: A test of drug-design methodologies, Trends Pharmacol. Sci., 16, 67, 10.1016/S0165-6147(00)88980-4 Wilson, 1997, Escape mutants of HIV-1 proteinase: Enzymic efficiency and susceptibility to inhibition, Biochim. Biophys. Acta, 1339, 113, 10.1016/S0167-4838(96)00224-5 Winslow, 1995, HIV protease inhibitors, AIDS, 9, S183 Winters, 1998, Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment, J. Virol., 72, 5303, 10.1128/JVI.72.6.5303-5306.1998 Wlodawer, 1993, Structure-based inhibitors of HIV-1 protease, Annu. Rev. Biochem., 62, 543, 10.1146/annurev.bi.62.070193.002551 Wlodawer, 1998, Inhibitors of HIV-1 protease: A major success of structure-assisted drug design, Annu. Rev. Biophys. Biomol. Struct., 27, 249, 10.1146/annurev.biophys.27.1.249 Wlodawer, 1989, Conserved folding in retroviral proteases: Crystal structure of a synthetic HIV-1 protease, Science, 245, 616, 10.1126/science.2548279 Xie, 1998, Thermodynamics and proton uptake for pepstatin binding to retroviral and eukaryotic aspartic proteases, Adv. Exp. Med. Biol., 436, 381, 10.1007/978-1-4615-5373-1_53 Xie, 1999, Drug resistant mutations can affect dimer stability of HIV-1 protease at neutral pH, Protein Sci., 8, 1702, 10.1110/ps.8.8.1702 Xie, 1999, Real-time measurements of dark substrate catalysis, Protein Sci. Yamazaki, 1994, NMR and X-ray evidence that the HIV protease catalytic aspartyl groups are protonated in the complex formed by the protease and a non-peptide cyclic urea-based inhibitor, J. Am. Chem. Soc., 116, 10791, 10.1021/ja00102a057 Yu, 1996, Irreversiible inhibition of the HIV-1 protease: Targeting alkylating agents to the catalytic aspartate groups, J. Am. Chem. Soc., 118, 5846, 10.1021/ja954069w Zennou, 1998, Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo, J. Virol., 72, 3300, 10.1128/JVI.72.4.3300-3306.1998 Zhang, 1997, Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites, J. Virol., 71, 6662, 10.1128/JVI.71.9.6662-6670.1997 Zhang, 1991, Dissociative inhibition of dimeric enzymes, J. Biol. Chem., 266, 15591, 10.1016/S0021-9258(18)98445-0 Zutshi, 1997, Targeting the dimerization interface of HIV-1 protease-inhibition with cross-linked interfacial peptides, J. Am. Chem. Soc., 119, 4841, 10.1021/ja962496j